The CWRU Cancer Center Flow Cytometry resource is an established core that has a history of stable direction (Director: 15 years), management (6 & 7 years), NCI funding (13 years), and supporting cancer research with up-to-date, well-maintained flow cytometry and cell sorting instrumentation. The director, James Jacobberger, has a major interest in the science of Cytometry. Considered to be one of the field?s leaders, Dr. Jacobberger has a strong commitment to developing and maintaining a robust and sophisticated Flow Cytometry Core that is especially flexible and can respond to the diverse needs of the CWRU Cancer Center investigators. The manager, Mr. Sramkoski, is a trained Medical Technician, with specialization in Cytometry who is equally committed. Together they have 37 years experience in the field and provide a superior level of expertise and guidance during experimental design and protocol development. Use of the core has grown steadily for 15 years with an especially sharp increase in recent years. In any one year there are approximately 70 principal investigators (users) drawn from a base of approximately 127 active investigators who have used the facility within the first few years. (Since inception, the core has assisted 167 investigators.) The facility currently operates at full capacity with two instruments - a single laser 4 color analyzer and a 4 laser, 4 color, 6 parameter cell sorter. An order has been placed for a new Becton-Dickinson LSR analyzer with 3 lasers and 6 color capability. A grant has been submitted for an additional (high speed) cell sorter that will have 5 lasers and 8 color capacity. Acquisition of these instruments will ensure that the facility can continue to support growth of cancer research at CWRU. Since the last competitive renewal an Assistant Manager has been hired to handle the increased work load and to establish a staining service. The facility operates with planned development that does and will provide outstanding technology and science in Cytometry for the Cancer Center?s membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA043703-13
Application #
6501432
Study Section
Project Start
1991-09-30
Project End
2006-07-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
13
Fiscal Year
2001
Total Cost
$78,870
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726

Showing the most recent 10 out of 1227 publications